Kura Oncology shares preclinical data for NSCLC treatment
Kura Oncology has shared positive preclinical data which supports the development of its next-generation farnesyl transferase inhibitor (FTI) KO-2806 in combination with KRASG12C inhibitors for the treatment of non-small cell lung cancer (NSCLC).
The findings of this data have been presented at the 5th RAS-Targeted Drug Development Summit in Boston, US.
The company plans to dose its first patient in its phase 1 dose-escalation trial of KO-2806 in the second half of 2023, as well as planning to assess the drug in dose-escalation combination cohorts for the treatment of other advanced solid tumours including clear cell renal cell carcinoma (ccRCC) and KRASg12c NSCLC.
Francis Burrows, PhD, senior vice president of Translational Research at Kura Oncology, commented: “Despite advances with KRAS-targeted therapies, a significant unmet need remains for patients with KRASG12C-mutant NSCLC as acquired resistance occurs early and often. We are highly encouraged by these first preclinical data for KO-2806, which demonstrate the potential for FTIs as a mechanism-based combination agent to enhance antitumor activity of targeted therapies, such as KRASG12C inhibitors.”
Genentech, a member of the Roche Group, has announced positive results from the phase 3 …
Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s …
AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the …